Obsessive-Compulsive Disorder

5
Pipeline Programs
6
Companies
8
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
SERTRALINE HYDROCHLORIDEApproved
sertraline
Unknown Company
oral2026

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biohaven
BiohavenNEW HAVEN, CT
3 programs
1
2
TroriluzolePhase 3Small Molecule1 trial
TroriluzolePhase 3Small Molecule1 trial
TroriluzolePhase 2/3Small Molecule1 trial
Active Trials
NCT03299166CompletedEst. Dec 2025
NCT04693351CompletedEst. Apr 2025
NCT04641143CompletedEst. Oct 2025
UP
UCB PharmaBelgium - Brussels
1 program
1
SertralinePhase 2/31 trial
Active Trials
NCT00299611Terminated12Est. Apr 2008
BrainsWay
BrainsWayJerusalem, Israel
2 programs
BrainsWay Deep TMS HAC/H7-CoilN/A1 trial
BrainsWay Deep TMS HAC/H7-CoilN/A1 trial
Active Trials
NCT07116785RecruitingEst. Dec 2028
NCT05404360UnknownEst. Jun 2024
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Personalized Computer ProgramN/A1 trial
Active Trials
NCT03855943Unknown100Est. Jun 2024
Varian Medical Systems
1 program
fMRI and DTIN/A1 trial
Active Trials
NCT04688554CompletedEst. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BiohavenTroriluzole
BiohavenTroriluzole
BiohavenTroriluzole
UCB PharmaSertraline
BrainsWayBrainsWay Deep TMS HAC/H7-Coil
BrainsWayBrainsWay Deep TMS HAC/H7-Coil
Varian Medical SystemsfMRI and DTI
Jerusalem PharmaceuticalsPersonalized Computer Program

Clinical Trials (8)

Total enrollment: 112 patients across 8 trials

NCT04693351BiohavenTroriluzole

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Start: Jan 2021Est. completion: Apr 2025
Phase 3Completed
NCT04641143BiohavenTroriluzole

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Start: Dec 2020Est. completion: Oct 2025
Phase 3Completed
NCT03299166BiohavenTroriluzole

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

Start: Dec 2017Est. completion: Dec 2025
Phase 2/3Completed
NCT00299611UCB PharmaSertraline

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

Start: Nov 2005Est. completion: Apr 200812 patients
Phase 2/3Terminated
NCT07116785BrainsWayBrainsWay Deep TMS HAC/H7-Coil

Accelerated Rotational Field Deep TMS for Treating OCD

Start: Sep 2023Est. completion: Dec 2028
N/ARecruiting
NCT05404360BrainsWayBrainsWay Deep TMS HAC/H7-Coil

Evaluation of the Long Term Efficacy and Durability of the BrainsWay Deep TMS in OCD Subjects

Start: Aug 2022Est. completion: Jun 2024
N/AUnknown
NCT04688554Varian Medical SystemsfMRI and DTI

Psychosocial, Behavioral, and Radiologic Changes Following Radiosurgery for Benign Neurologic Disease

Start: Aug 2020Est. completion: Feb 2024
N/ACompleted
NCT03855943Jerusalem PharmaceuticalsPersonalized Computer Program

Evaluating the Effects of a Computerized Training Program Coupled With Cognitive Behavioral Therapy (CBT) for OCD.

Start: Apr 2019Est. completion: Jun 2024100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 112 patients
6 companies competing in this space